NASDAQ · PGNY

Progyny, Inc.

$31.59 +$0.40 (+1.28%) 1D Pre-market

Key Metrics

$2.44B
Market cap
36.09×
P/E · TTM
$1.29B
Revenue · TTM
$67.69M
Net income
EPS · TTM $0.76
Dividend yield
Free cash flow $184.42M
Beta · 1Y 0.54
EBITDA · TTM $111.10M
Gross margin 24.1%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 8
    The stock moved +23.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 8
  • Apr 10
    From its Feb 2 high, the share price fell 33%.

    Peak close $24.21 on Feb 2; trough close $16.30 on Apr 10. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -33%
  • Feb 27
    The stock moved -20.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 27

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$2.44B
Enterprise value
Shares outstanding78.3M
52-wk range$16.10 – $33.07
Avg volume · 20D1.1M
Net cash
Book value / share$4.92
IndustryServices-Misc Health & Allied Services, Nec
ExchangeNASDAQ
About Progyny, Inc.
IPO dateOct 25, 2019
Employees856

Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E36.09
P/S1.89
P/FCF13.25
EV/EBITDA
EV/Sales
Graham №$9.16

Profitability

Gross 24.1%
Operating 8.2%
Net 5.2%
FCF 14.3%
ROE / ROIC 15.7% · 31.6%

Financial Health

Current ratio2.13
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$265.81M

Cash Flow · TTM

Operating CF $206.33M
Capex −$21.91M
Free cash flow $184.42M
Buybacks $200.26M
Dividends paid
Shareholder yield 8.2%

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

8.9
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$9.16 vs $31.59
Trades 3.4× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings